{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T06:25:30Z","timestamp":1794464730799,"version":"4.9.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Castration-resistant prostate cancer demonstrates intrinsic or acquired resistance to second-generation androgen-targeted therapies, posing a challenge in clinical treatment. In this study, on the basis of in vivo self-assembly nanotechnology, we designed a PSMA-targeted nano-PROTAC with a proximity degradation effect. Nano-PROTAC not only precisely degrades the AR receptor but also cleverly degrades the HSP90 that is closely bound to the AR receptor, utilizing the spatial distance self-adaptive characteristics of its nanostructure. In the 22Rv1 cell model, Nano-PROTAC degraded 80% of the AR protein and 65% of the HSP90 protein. More importantly, nano-PROTAC could degrade 74% of the AR splice variant AR-V7 protein, showing the potential ability to overcome drug resistance. We further constructed an enzalutamide-resistant xenograft tumor mouse model to evaluate the therapeutic effect of the Nano-PROTAC. Compared with the combination treatment group of AR and HSP90 inhibitors (enzalutamide and pimitespib), the nano-PROTAC treatment group presented a high tumor growth inhibition value of up to 78% and a median survival extension of 15 days. Nano-PROTACs that simultaneously degrade AR and HSP90 can overcome the resistance of prostate cancer to PSMA- and AR-positive castration-resistant prostate cancer, except for neuroendocrine prostate cancer, which provides a new therapeutic strategy for the treatment of prostate cancer.<\/jats:p>","DOI":"10.1038\/s41392-025-02444-z","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T23:01:55Z","timestamp":1760482915000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["In vivo self-assembled nano-PROTAC for the dual degradation of AR and HSP90 to overcome castration-resistant prostate cancer resistance"],"prefix":"10.1038","volume":"10","author":[{"given":"Fei-Ya","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni-Yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Yuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Kuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Xi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuan","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Ze","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Ze","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Wei","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nian-Zeng","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"2444_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"2444_CR2","doi-asserted-by":"crossref","unstructured":"Predicting prognosis in castration-resistant prostate cancer. Nat. Rev. Cancer 12, 736\u2013736 (2012).","DOI":"10.1038\/nrc3391"},{"key":"2444_CR3","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1158\/1078-0432.CCR-24-3660","volume":"31","author":"L Zhang","year":"2025","unstructured":"Zhang, L. Emerin dysregulation drives the very-small-nuclear phenotype and lineage plasticity that associates with a clinically aggressive subtype of prostate cancer. Clin. Cancer Res 31, 2034\u20132045 (2025).","journal-title":"Clin. Cancer Res"},{"key":"2444_CR4","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41591-021-01244-6","volume":"27","author":"MX He","year":"2021","unstructured":"He, M. X. et al. Transcriptional mediators of treatment resistance in lethal prostate cancer. Nat. Med. 27, 426\u2013433 (2021).","journal-title":"Nat. Med."},{"key":"2444_CR5","doi-asserted-by":"publisher","first-page":"103625","DOI":"10.1016\/j.ebiom.2021.103625","volume":"72","author":"HM Lin","year":"2021","unstructured":"Lin, H. M. et al. Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase. EBioMedicine 72, 103625 (2021).","journal-title":"EBioMedicine"},{"key":"2444_CR6","doi-asserted-by":"publisher","first-page":"5567","DOI":"10.1021\/acs.jmedchem.3c02177","volume":"67","author":"M Xiao","year":"2024","unstructured":"Xiao, M. et al. Structure-activity relationship (SAR) studies of novel monovalent AR\/AR-V7 dual degraders with potent efficacy against advanced prostate cancer. J. Med. Chem. 67, 5567\u20135590 (2024).","journal-title":"J. Med. Chem."},{"key":"2444_CR7","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/s41419-021-04162-0","volume":"12","author":"Y Liu","year":"2021","unstructured":"Liu, Y. et al. Selective degradation of AR-V7 to overcome castration resistance of prostate cancer. Cell Death Dis. 12, 857 (2021).","journal-title":"Cell Death Dis."},{"key":"2444_CR8","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1158\/1535-7163.MCT-16-0241","volume":"15","author":"L Chen","year":"2016","unstructured":"Chen, L. et al. Cotargeting HSP90 and its client proteins for treatment of prostate cancer. Mol. Cancer Ther. 15, 2107\u20132118 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"2444_CR9","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s12038-007-0051-y","volume":"32","author":"L Neckers","year":"2007","unstructured":"Neckers, L. Heat shock protein 90: the cancer chaperone. J. Biosci. 32, 517\u2013530 (2007).","journal-title":"J. Biosci."},{"key":"2444_CR10","doi-asserted-by":"publisher","first-page":"e17692","DOI":"10.1371\/journal.pone.0017692","volume":"6","author":"SK Lyman","year":"2011","unstructured":"Lyman, S. K. et al. High-content, high-throughput analysis of cell cycle perturbations induced by the HSP90 inhibitor XL888. PLoS ONE 6, e17692 (2011).","journal-title":"PLoS ONE"},{"key":"2444_CR11","first-page":"306","volume":"18","author":"WB Pratt","year":"1997","unstructured":"Pratt, W. B. & Toft, D. O. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr. Rev. 18, 306\u2013360 (1997).","journal-title":"Endocr. Rev."},{"key":"2444_CR12","doi-asserted-by":"publisher","first-page":"442","DOI":"10.7164\/antibiotics.23.442","volume":"23","author":"C DeBoer","year":"1970","unstructured":"DeBoer, C., Meulman, P. A., Wnuk, R. J. & Peterson, D. H. Geldanamycin, a new antibiotic. J. Antibiot. 23, 442\u2013447 (1970).","journal-title":"J. Antibiot."},{"key":"2444_CR13","doi-asserted-by":"publisher","first-page":"22796","DOI":"10.1074\/jbc.271.37.22796","volume":"271","author":"EG Mimnaugh","year":"1996","unstructured":"Mimnaugh, E. G., Chavany, C. & Neckers, L. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J. Biol. Chem. 271, 22796\u201322801 (1996).","journal-title":"J. Biol. Chem."},{"key":"2444_CR14","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1530\/ERC-14-0541","volume":"22","author":"MM Centenera","year":"2015","unstructured":"Centenera, M. M. et al. Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms. Endocr. Relat. Cancer 22, 805\u2013818 (2015).","journal-title":"Endocr. Relat. Cancer"},{"key":"2444_CR15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/nrurol.2014.320","volume":"12","author":"AA Azad","year":"2015","unstructured":"Azad, A. A., Zoubeidi, A., Gleave, M. E. & Chi, K. N. Targeting heat shock proteins in metastatic castration-resistant prostate cancer. Nat. Rev. Urol. 12, 26\u201336 (2015).","journal-title":"Nat. Rev. Urol."},{"key":"2444_CR16","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1196\/annals.1391.012","volume":"1113","author":"P Workman","year":"2007","unstructured":"Workman, P., Burrows, F., Neckers, L. & Rosen, N. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann. N. Y. Acad. Sci. 1113, 202\u2013216 (2007).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"2444_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-481","volume":"10","author":"PK Karkoulis","year":"2010","unstructured":"Karkoulis, P. K., Stravopodis, D. J., Margaritis, L. H. & Voutsinas, G. E. 17-Allylamino-17-demethoxygeldanamycin induces downregulation of critical Hsp90 protein clients and results in cell cycle arrest and apoptosis of human urinary bladder cancer cells. BMC Cancer 10, 481 (2010).","journal-title":"BMC Cancer"},{"key":"2444_CR18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1379\/1466-1268(2002)007<0055:EOGOAR>2.0.CO;2","volume":"7","author":"DK Vanaja","year":"2002","unstructured":"Vanaja, D. K., Mitchell, S. H., Toft, D. O. & Young, C. Y. Effect of geldanamycin on androgen receptor function and stability. Cell Stress Chaperones 7, 55\u201364 (2002).","journal-title":"Cell Stress Chaperones"},{"key":"2444_CR19","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/j.juro.2007.05.120","volume":"178","author":"CR Williams","year":"2007","unstructured":"Williams, C. R., Tabios, R., Linehan, W. M. & Neckers, L. Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model. J. Urol. 178, 1528\u20131532 (2007).","journal-title":"J. Urol."},{"key":"2444_CR20","doi-asserted-by":"publisher","first-page":"4152","DOI":"10.1200\/JCO.2005.00.612","volume":"23","author":"U Banerji","year":"2005","unstructured":"Banerji, U. et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J. Clin. Oncol. 23, 4152\u20134161 (2005).","journal-title":"J. Clin. Oncol."},{"key":"2444_CR21","doi-asserted-by":"publisher","first-page":"7940","DOI":"10.1158\/1078-0432.CCR-08-0221","volume":"14","author":"EI Heath","year":"2008","unstructured":"Heath, E. I. et al. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin. Cancer Res. 14, 7940\u20137946 (2008).","journal-title":"Clin. Cancer Res."},{"key":"2444_CR22","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1200\/JCO.2009.25.0415","volume":"28","author":"RK Ramanathan","year":"2010","unstructured":"Ramanathan, R. K. et al. Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors. J. Clin. Oncol. 28, 1520\u20131526 (2010).","journal-title":"J. Clin. Oncol."},{"key":"2444_CR23","doi-asserted-by":"publisher","first-page":"12460","DOI":"10.1021\/acs.jmedchem.2c01164","volume":"65","author":"A Wang","year":"2022","unstructured":"Wang, A. et al. Design, synthesis, and biological evaluation of androgen receptor degrading and antagonizing bifunctional steroidal analogs for the treatment of advanced prostate cancer. J. Med. Chem. 65, 12460\u201312481 (2022).","journal-title":"J. Med. Chem."},{"key":"2444_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23194-w","volume":"12","author":"C Zhang","year":"2021","unstructured":"Zhang, C. et al. Semiconducting polymer nano-PROTACs for activatable photo-immunometabolic cancer therapy. Nat. Commun. 12, 2934 (2021).","journal-title":"Nat. Commun."},{"key":"2444_CR25","doi-asserted-by":"publisher","first-page":"104376","DOI":"10.1016\/j.drudis.2025.104376","volume":"30","author":"M Cornu","year":"2025","unstructured":"Cornu, M., Lemaitre, T., Kieffer, C. & Voisin-Chiret, A. S. PROTAC 2.0: expanding the frontiers of targeted protein degradation. Drug Discov. Today 30, 104376 (2025).","journal-title":"Drug Discov. Today"},{"key":"2444_CR26","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","volume":"181","author":"GM Burslem","year":"2020","unstructured":"Burslem, G. M. & Crews, C. M. Proteolysis-targeting chimeras as therapeutics and tools for biological discovery. Cell 181, 102\u2013114 (2020).","journal-title":"Cell"},{"key":"2444_CR27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","volume":"7","author":"L Zhao","year":"2022","unstructured":"Zhao, L., Zhao, J., Zhong, K., Tong, A. & Jia, D. Targeted protein degradation: mechanisms, strategies and application. Signal Transduct. Target. Ther. 7, 113 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2444_CR28","doi-asserted-by":"publisher","first-page":"e2207439","DOI":"10.1002\/advs.202207439","volume":"10","author":"HJ Liu","year":"2023","unstructured":"Liu, H. J. et al. Glutathione-scavenging nanoparticle-mediated PROTACs Delivery for targeted protein degradation and amplified antitumor effects. Adv. Sci. 10, e2207439 (2023).","journal-title":"Adv. Sci."},{"key":"2444_CR29","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M B\u00e9k\u00e9s","year":"2022","unstructured":"B\u00e9k\u00e9s, M., Langley, D. R. & Crews, C. M. PROTAC targeted protein degraders: the past is prologue. Nat. Rev. Drug Discov. 21, 181\u2013200 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2444_CR30","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41392-024-01983-1","volume":"9","author":"L Yang","year":"2024","unstructured":"Yang, L. et al. Sequential responsive nano-PROTACs for precise intracellular delivery and enhanced degradation efficacy in colorectal cancer therapy. Signal Transduct. Target. Ther. 9, 275 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2444_CR31","doi-asserted-by":"publisher","first-page":"103513","DOI":"10.1016\/j.drudis.2023.103513","volume":"28","author":"H Li","year":"2023","unstructured":"Li, H., Zhang, Q., Feng, Q., You, Q. & Guo, X. The development of small molecules targeting methyltransferase-like 3. Drug Discov. Today 28, 103513 (2023).","journal-title":"Drug Discov. Today"},{"key":"2444_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40244-7","volume":"14","author":"L Zhou","year":"2023","unstructured":"Zhou, L. et al. DNA framework-engineered chimeras platform enables selectively targeted protein degradation. Nat. Commun. 14, 4510 (2023).","journal-title":"Nat. Commun."},{"key":"2444_CR33","doi-asserted-by":"publisher","first-page":"e202308049","DOI":"10.1002\/anie.202308049","volume":"62","author":"NY Zhang","year":"2023","unstructured":"Zhang, N. Y. et al. Nano proteolysis targeting chimeras (PROTACs) with anti-Hook effect for tumor therapy. Angew. Chem. Int. Ed. Engl. 62, e202308049 (2023).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"2444_CR34","doi-asserted-by":"publisher","first-page":"7879","DOI":"10.1021\/jacs.2c12824","volume":"145","author":"F Yang","year":"2023","unstructured":"Yang, F. et al. Targeted biomolecule regulation platform: a split-and-mix PROTAC approach. J. Am. Chem. Soc. 145, 7879\u20137887 (2023).","journal-title":"J. Am. Chem. Soc."},{"key":"2444_CR35","doi-asserted-by":"publisher","first-page":"6263","DOI":"10.1021\/acs.jmedchem.3c00013","volume":"66","author":"Z Wang","year":"2023","unstructured":"Wang, Z. et al. Persistent degradation of HER2 protein by hybrid nanoPROTAC for programmed cell death. J. Med. Chem. 66, 6263\u20136273 (2023).","journal-title":"J. Med. Chem."},{"key":"2444_CR36","doi-asserted-by":"publisher","first-page":"e202218128","DOI":"10.1002\/anie.202218128","volume":"62","author":"W Su","year":"2023","unstructured":"Su, W. et al. Targeted degradation of PD-L1 and activation of the STING pathway by carbon-dot-based PROTACs for cancer immunotherapy. Angew. Chem. Int. Ed. Engl. 62, e202218128 (2023).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"2444_CR37","doi-asserted-by":"publisher","first-page":"4378","DOI":"10.1039\/D3NR06059D","volume":"16","author":"J Zhong","year":"2024","unstructured":"Zhong, J., Zhao, R., Wang, Y., Su, Y. X. & Lan, X. Nano-PROTACs: state of the art and perspectives. Nanoscale 16, 4378\u20134391 (2024).","journal-title":"Nanoscale"},{"key":"2444_CR38","doi-asserted-by":"publisher","first-page":"872729","DOI":"10.3389\/fcell.2022.872729","volume":"10","author":"MR Burke","year":"2022","unstructured":"Burke, M. R., Smith, A. R. & Zheng, G. Overcoming cancer drug resistance utilizing PROTAC technology. Front. Cell Dev. Biol. 10, 872729 (2022).","journal-title":"Front. Cell Dev. Biol."},{"key":"2444_CR39","doi-asserted-by":"publisher","first-page":"958","DOI":"10.7150\/thno.51478","volume":"11","author":"SJ Moon","year":"2021","unstructured":"Moon, S. J. et al. Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer. Theranostics 11, 958\u2013973 (2021).","journal-title":"Theranostics"},{"key":"2444_CR40","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor, O. et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 385, 1091\u20131103 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2444_CR41","doi-asserted-by":"publisher","first-page":"e2301162","DOI":"10.1002\/adhm.202301162","volume":"12","author":"YL Fan","year":"2023","unstructured":"Fan, Y. L. et al. Programmable peptides activated macropinocytosis for direct cytosolic delivery. Adv. Health. Mater. 12, e2301162 (2023).","journal-title":"Adv. Health. Mater."},{"key":"2444_CR42","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/phar.2339","volume":"39","author":"M van Nuland","year":"2019","unstructured":"van Nuland, M. et al. Exposure-response assessment of enzalutamide and its major metabolites in a real-world cohort of patients with metastatic castration-resistant prostate cancer. Pharmacotherapy 39, 1137\u20131145 (2019).","journal-title":"Pharmacotherapy"},{"key":"2444_CR43","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/nchembio.2538","volume":"14","author":"CM Olson","year":"2018","unstructured":"Olson, C. M. et al. Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. Nat. Chem. Biol. 14, 163\u2013170 (2018).","journal-title":"Nat. Chem. Biol."},{"key":"2444_CR44","doi-asserted-by":"publisher","first-page":"e2109432","DOI":"10.1002\/adma.202109432","volume":"34","author":"M Mamuti","year":"2022","unstructured":"Mamuti, M. et al. A polyvalent peptide CD40 nanoagonist for targeted modulation of dendritic cells and amplified cancer immunotherapy. Adv. Mater. 34, e2109432 (2022).","journal-title":"Adv. Mater."},{"key":"2444_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12848-5","volume":"10","author":"H-W An","year":"2019","unstructured":"An, H.-W. et al. A tumour-selective cascade activatable self-detained system for drug delivery and cancer imaging. Nat. Commun. 10, 4861 (2019).","journal-title":"Nat. Commun."},{"key":"2444_CR46","doi-asserted-by":"publisher","first-page":"10753","DOI":"10.1021\/jacs.4c00826","volume":"146","author":"N Chen","year":"2024","unstructured":"Chen, N. et al. Sulfatase-induced in situ formulation of antineoplastic supra-PROTACs. J. Am. Chem. Soc. 146, 10753\u201310766 (2024).","journal-title":"J. Am. Chem. Soc."},{"key":"2444_CR47","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.cell.2016.03.003","volume":"165","author":"FE Morreale","year":"2016","unstructured":"Morreale, F. E. & Walden, H. Types of ubiquitin ligases. Cell 165, 248\u2013248.e241 (2016).","journal-title":"Cell"},{"key":"2444_CR48","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/aps.2014.52","volume":"35","author":"H Yan","year":"2014","unstructured":"Yan, H. et al. MG132, a proteasome inhibitor, enhances LDL uptake in HepG2 cells in vitro by regulating LDLR and PCSK9 expression. Acta Pharm. Sin. 35, 994\u20131004 (2014).","journal-title":"Acta Pharm. Sin."},{"key":"2444_CR49","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cell.2017.04.023","volume":"169","author":"GA Collins","year":"2017","unstructured":"Collins, G. A. & Goldberg, A. L. The logic of the 26S proteasome. Cell 169, 792\u2013806 (2017).","journal-title":"Cell"},{"key":"2444_CR50","doi-asserted-by":"publisher","first-page":"6125","DOI":"10.1002\/adma.201502598","volume":"27","author":"D Zhang","year":"2015","unstructured":"Zhang, D. et al. In situ formation of nanofibers from purpurin18-peptide conjugates and the assembly induced retention effect in tumor sites. Adv. Mater. 27, 6125\u20136130 (2015).","journal-title":"Adv. Mater."},{"key":"2444_CR51","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1158\/0008-5472.CAN-20-1965","volume":"81","author":"L Gao","year":"2021","unstructured":"Gao, L. et al. KIF15-mediated stabilization of AR and AR-V7 contributes to enzalutamide resistance in prostate cancer. Cancer Res. 81, 1026\u20131039 (2021).","journal-title":"Cancer Res."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02444-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02444-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02444-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T23:01:57Z","timestamp":1760482917000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02444-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2444"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02444-z","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"346"}}